Electromagnetic Interference Shielding and Joule Heating Properties of Flexible, Lightweight, and Hydrophobic MXene/Nickel-Coated Polyester Fabrics Manufactured by Dip-Dry Coating and Electroless Plating.

High-performance electromagnetic interference (EMI) shielding materials with high flexibility, low density, and hydrophobic surface are crucial for modern integrated electronics and telecommunication systems in advanced industries like aerospace, military, artificial intelligence, and wearable electronics. In this study, we present flexible and hydrophobic MXene/Ni-coated polyester (PET) fabrics featuring a double-layered structure, fabricated via a facile and scalable dip-dry coating process followed by electroless nickel plating. Increasing the dip-dry coating iterations up to 10 cycles boosts the MXene loading content (∼31 wt %) and electrical conductivity (∼86 S/cm) of MXene-coated PET fabrics, while maintaining constant porosity (∼95%). The addition of a Ni layer enhances hydrophobicity, achieving a high water contact angle of ∼114° compared to only MXene-coated PET fabrics (∼49°). Furthermore, the 30 µm thick MXene/Ni-coated PET fabric demonstrates superior electrical conductivity (∼113.8 S/cm) and EMI shielding effectiveness (∼35.7 dB at 8-12 GHz) compared to only MXene- or Ni-coated PET fabrics. The EMI shielding performance of the MXene/Ni-coated PET fabric remains more stable in an air environment than only MXene-coated fabrics due to the outer Ni layer with excellent hydrophobicity and oxidation stability. Additionally, the MXene/Ni-coated PET fabric exhibits impressive Joule heating performance, swiftly converting electrical energy into heat and reaching high steady-state temperatures (32-92 °C) at low applied voltages (0.5-1.5 V).

Validation of the Texas Hepatocellular Carcinoma Risk Index Predictive Model for Hepatocellular Carcinoma in Asian Cohort.

Hepatocellular carcinoma (HCC) represents a significant global health burden, with its incidence and mortality rates varying significantly across different geographic regions. This variance is largely attributed to differences in the prevalence of risk factors such as hepatitis B and C infections, and alcohol consumption, as well as genetic predispositions that are distinct between Eastern and Western populations. Moreover, the impact of racial and ethnic diversity on the disease's epidemiology further complicates the global understanding and prediction of HCC. Such disparities highlight the critical need to evaluate the applicability of predictive models across diverse populations, acknowledging that a model developed in one region may not necessarily translate with the same accuracy or effectiveness when applied to another, because of these underlying epidemiologic and genetic differences. In this study, we aimed to assess the cross-regional applicability and accuracy of an HCC prediction model (Texas hepatocellular carcinoma risk index [THCC-RI] predictive model) originally developed in Western populations, within an Eastern context.1,2.

Reduced-Dose or Discontinuation of Bevacizumab Might Be Considered after Variceal Bleeding in Patients with Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab: Case Reports.

Background and Objectives: Variceal bleeding (VB) is the most concerning condition that is difficult to treat after atezolizumab/bevacizumab in patients with advanced hepatocellular carcinoma (HCC). Materials and Methods: We would like to introduce the cases of two patients who underwent bevacizumab reduction or discontinuation when VB occurred after atezolizumab/bevacizumab. Results: VB occurred in two patients who showed good tumor response after atezolizumab/bevacizumab treatment, and all VBs were successfully treated with endoscopic variceal ligations. In the first patient, VB did not occur as the tumor response decreased after a 50% reduction in bevacizumab. In the second patient, VB occurred again after a 50% bevacizumab reduction, so bevacizumab was discontinued and treatment with atezolizumab alone has been successfully maintained. Conclusions: Accordingly, we would like to suggest that considering bevacizumab dose reduction instead of changing to tyrosine kinase inhibitor may be a good clinical choice in atezolizumab/bevacizumab patients who develop VB.

Complications of immunotherapy in advanced hepatocellular carcinoma.

Immune checkpoint inhibitors (ICIs) are highly effective in cancer treatment. However, the risks associated with the treatment must be carefully balanced against the therapeutic benefits. Immune-related adverse events (irAEs) are generally unpredictable and may persist over an extended period. In this review, we analyzed common irAEs reported in highly cited original articles and systematic reviews. The prevalent adverse reactions include fatigue, pyrexia, rash, pruritus, diarrhea, decreased appetite, nausea, abdominal pain, constipation, hepatitis, and hypothyroidism. Therefore, it is crucial to conduct evaluations not only of gastrointestinal organs but also of cardiac, neurologic, endocrine (including the frequently affected thyroid), and ophthalmic systems before commencing ICIs. This review further explores commonly reported types of irAEs, specific irAEs associated with each ICI agent, rare yet potentially fatal irAEs, and available treatment options for managing them.